

Publikationsliste 12/2016

1. Originalarbeiten

1. Beer M, Montani M, Gerhardt J, Wild PJ, Hany TF, Hermanns T, **Müntener, M**, Kristiansen, G. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. *Prostate*. 2012;72(3):318-25.
Impact factor: 3.778 (2015)
2. Feicke A, Baumgartner M, Talimi S, Schmid DM, Seifert HH, **Müntener M**, Fatzer, M, Sulser, T, Strebel, RT. Robotic-assisted laparoscopic extended pelvic lymph node dissection for prostate cancer: surgical technique and experience with the first 99 cases. *Eur Urol*. 2009;55(4):876-83.
Impact factor: 14.976 (2015)
3. Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T, **Müntener, M**, Kristiansen, G. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. *Am J Pathol*. 2012;180(2):848-61.
Impact factor: 4.206 (2015)
4. Gerhardt J, Steinbrech C, Buchi O, Behnke S, Bohnert A, Fritzsche F, Liewen, H, Stenner, F, Wild, P, Hermanns, T, **Müntener, M**, Dietel, M, Jung, K, Stephan, C, Kristiansen, G. The androgen-regulated Calcium-Activated Nucleotidase 1 (CANT1) is commonly overexpressed in prostate cancer and is tumor-biologically relevant in vitro. *Am J Pathol*. 2011;178(4):1847-60.
Impact factor: 4.206 (2015)
5. Hermanns T, Gross O, Kranzbuhler B, Hefermehl LJ, Poyet C, Muller A, Yap, SA, Michel, MS, Eberli, D, **Müntener, M**, Zimmermann, M, Sulser, T, Seifert, HH. Ablative efficiency of 532-nm laser vaporization compared to transurethral resection of the prostate: results from a prospective three-dimensional ultrasound volumetry study. *World J Urol*. 2014;32(5):1267-74.
Impact factor: 2.397 (2015)
6. Hermanns T, Strebel DD, Hefermehl LJ, Gross O, Mortezaavi A, Muller A, Eberli, D, **Müntener, M**, Michel, MS, Meier, AH, Sulser, T, Seifert, HH. Lithium triborate laser vaporization of the prostate using the 120 W, high performance system laser: high performance all the way? *J Urol*. 2011;185(6):2241-7.
Impact factor: 4.700 (2015)

7. Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, Hofmann I, Hermanns T, Seifert H, **Müntener, M**, Provenzano, M, Sulser, T, Behnke, S, Gerhardt, J, Mortezaei, A, Wild, P, Hofstadter, F, Burger, M, Moch, H, Kristiansen, G. Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores.
BMC Cancer. 2010;10:341.
Impact factor: 3.265 (2015)
8. Montani M, Hermanns T, **Müntener M**, Wild P, Sulser T, Kristiansen G. Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression.
Virchows Arch. 2013;462(4):437-43.
Impact factor: 2.613 (2015)
9. **Müntener M**, Egli J, Knoenagel H. The endourological management of long ureteric defects.
BJU Int. 2003;92(6):647-9.
Impact factor: 4.387 (2015)
10. **Müntener M**, Suter S, Hauri D, Sulser T. Long-term experience with surgical and conservative treatment of penile fracture.
J Urol. 2004;172(2):576-9.
Impact factor: 4.700 (2015)
11. **Müntener M**, Aellig S, Kuettel R, Gehrlach C, Sulser T, Strebel RT. Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcome.
Eur Urol. 2007;52(2):510-5.
Impact factor: 14.976 (2015)
12. **Müntener M**, Aellig S, Kuttel R, Gehrlach C, Hauri D, Strebel RT. Peri-operative morbidity and changes in symptom scores after transurethral prostatectomy in Switzerland: results of an independent assessment of outcome.
BJU Int. 2006;98(2):381-3.
Impact factor: 4.387 (2015)
13. **Müntener M**, Epstein JI, Hernandez DJ, Gonzalgo ML, Mangold L, Humphreys E, Walsh, PC, Partin, AW, Nielsen, ME. Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy.
Eur Urol. 2008;53(4):767-75; discussion 75-6.
Impact factor: 14.976 (2015)
14. **Müntener M**, Fatzer M, Praz V, Straumann U, Strebel RT, John H. Local anesthesia for transurethral manipulations: is a transrectal periprostatic nerve block effective?
World J Urol. 2005;23(5):349-52.
Impact factor: 2.397 (2015)

15. **Muntener M**, Kunz U, Eichler K, Puhan M, Schmid DM, Sulser T, Strebel RT. Lowering the PSA threshold for prostate biopsy from 4 to 2.5 ng/ml: influence on cancer characteristics and number of men needed to biopt. *Urol Int.* 2010;84(2):141-6.
Impact factor: 1.313 (2015)
16. **Muntener M**, Nielsen ME, Romero FR, Schaeffer EM, Allaf ME, Brito FA, Pavlovich, CP, Kavoussi, LR, Jarrett, TW. Long-term oncologic outcome after laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma. *Eur Urol.* 2007;51(6):1639-44.
Impact factor: 14.976 (2015)
17. **Muntener M**, Patriciu A, Petrisor D, Mazilu D, Bagga H, Kavoussi L, Cleary, K, Stoianovici, D. Magnetic resonance imaging compatible robotic system for fully automated brachytherapy seed placement. *Urology.* 2006;68(6):1313-7.
Impact factor: 2.187 (2015)
18. **Muntener M**, Patriciu A, Petrisor D, Schar M, Ursu D, Song DY, Stoianovici, D. Transperineal prostate intervention: robot for fully automated MR imaging--system description and proof of principle in a canine model. *Radiology.* 2008;247(2):543-9.
Impact factor: 6.798 (2015)
19. **Muntener M**, Reitz A, Wefer B, Schurch B. Systemic augmentation of nitric oxide: is there an immediate effect on the urinary flow rate in healthy men? *Urol Int.* 2006;76(1):31-5.
Impact factor: 1.313 (2015)
20. **Muntener M**, Schaeffer EM, Romero FR, Nielsen ME, Allaf ME, Brito FA, Pavlovich, CP, Kavoussi, LR, Jarrett, TW. Incidence of local recurrence and port site metastasis after laparoscopic radical nephroureterectomy. *Urology.* 2007;70(5):864-8.
Impact factor: 2.187 (2015)
21. **Muntener M**, Schurch B, Wefer B, Reitz A. Systemic nitric oxide augmentation leads to a rapid decrease of the bladder outlet resistance in healthy men. *Eur Urol.* 2006;50(1):112-7; discussion 7-8.
Impact factor: 14.976 (2015)
22. Patriciu A, Petrisor D, **Muntener M**, Mazilu D, Schar M, Stoianovici D. Automatic brachytherapy seed placement under MRI guidance. *IEEE Trans Biomed Eng.* 2007;54(8):1499-506.
Impact factor: 2.468 (2015)
23. Poyet C, Hof D, Sulser T, **Muntener M**. Artificial prostate-specific antigen persistence after radical prostatectomy. *J Clin Oncol.* 2012;30(5):e62-3.
Impact factor: 20.982 (2015)

24. Reitz A, Bretscher S, Knapp PA, **Muntener M**, Wefer B, Schurch B. The effect of nitric oxide on the resting tone and the contractile behaviour of the external urethral sphincter: a functional urodynamic study in healthy humans. *Eur Urol.* 2004;45(3):367-73.
Impact factor: 14.976 (2015)
25. Reitz A, Knapp PA, **Muntener M**, Schurch B. Oral nitric oxide donors: a new pharmacological approach to detrusor-sphincter dyssynergia in spinal cord injured patients? *Eur Urol.* 2004;45(4):516-20.
Impact factor: 14.976 (2015)
26. Romero FR, **Muntener M**, Permpongkosol S, Kavoussi LR, Jarrett TW. Laparoscopic-assisted nephroureterectomy after radical cystectomy for transitional cell carcinoma. *Int Braz J Urol.* 2006;32(6):631-8; discussion 8-9.
Impact factor: 0.871 (2015)
27. Romero FR, Rais-Bahrami S, **Muntener M**, Brito FA, Jarrett TW, Kavoussi LR. Laparoscopic partial nephrectomy in obese and non-obese patients: comparison with open surgery. *Urology.* 2008;71(5):806-9.
Impact factor: 2.187 (2015)
28. Romero FR, Schaeffer EM, **Muntener M**, Trock B, Kavoussi LR, Jarrett TW. Oncologic outcomes of extravesical stapling of distal ureter in laparoscopic nephroureterectomy. *J Endourol.* 2007;21(9):1025-7.
Impact factor: 2.107 (2015)
29. Romero FR, Trapp C, **Muntener M**, Brito FA, Kavoussi LR, Jarrett TW. Total laparoscopic gastrocystoplasty: experimental technique in a porcine model. *Int Braz J Urol.* 2007;33(1):94-9; discussion 9.
Impact factor: 0.871 (2015)
30. Romero FR, Wagner A, Brito FA, **Muntener M**, Lima GC, Kavoussi LR. Refining the laparoscopic retroperitoneal lymph node dissection for testicular cancer. *Int Braz J Urol.* 2006;32(2):196-201.
Impact factor: 0.871 (2015)
31. Romero FR, Wagner AA, Bagga HS, **Muntener M**, Brito FA, Kavoussi LR. Laparoscopic treatment of simultaneous tumors in the liver and kidney. *Urol Int.* 2007;79(2):142-4.
Impact factor: 1.313 (2015)
32. Romero FR, Wagner AA, Trapp C, Permpongkosol S, **Muntener M**, Link RE, Kavoussi, LR. Transmesenteric laparoscopic pyeloplasty. *J Urol.* 2006;176(6 Pt 1):2526-9.
Impact factor: 4.700 (2015)

33. Rupp NJ, Schüffler PJ, Zhong Q, Falkner F, Rechsteiner M, Rüschoff JH, Fankhauser, C, Drach, M, Largo, R, Tremp, M, Poyet, C, Sulser, T, Kristiansen, G, Moch, H, Buhmann, J, **Müntener, M**#, Wild, PJ#. Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer.
Journal of Pathology Informatics 2016;7:3.
Impact factor: - (2015)
34. Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, **Muentener M**, Strebel, RT, Perucchini, D, Scheiner, D, Schaer, G, John, H, Reitz, A, Hauri, D, Schurch, B. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
J Urol. 2006;176(1):177-85.
Impact factor: 4.700 (2015)
35. Stenner-Liewen F, Liewen H, Cathomas R, Renner C, Petrausch U, Sulser T, Spanaus, K, Seifert, HH, Strebel, RT, Knuth, A, Samaras, P, **Müntener, M**. Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial.
J Cancer. 2013;4(7):597-605.
Impact factor: 3.609 (2015)
36. Stoianovici D, Song D, Petrisor D, Ursu D, Mazilu D, **Muntener M**, Schar, M, Patriciu, A. "MRI Stealth" robot for prostate interventions.
Minim Invasive Ther Allied Technol. 2007;16(4):241-8.
Impact factor: 1.279 (2015)
37. Stolzmann P, Kozomara M, Chuck N, **Muntener M**, Leschka S, Scheffel H, Alkadhi, H. In vivo identification of uric acid stones with dual-energy CT: diagnostic performance evaluation in patients.
Abdom Imaging. 2010;35(5):629-35.
Impact factor: 2.189 (2015)
38. Strebel RT, Leippold T, Luginbuehl T, **Muentener M**, Praz V, Hauri D. Chronic scrotal pain syndrome: management among urologists in Switzerland.
Eur Urol. 2005;47(6):812-6.
Impact factor: 14.976 (2015)
39. Strebel RT, **Muentener M**, Fatzer M, Crott C, John H, Hauri D, Schmid, DM. Neurovascular bundle block as predictor of postoperative erectile function after radical prostatectomy.
Int J Impot Res. 2005;17(6):510-2.
Impact factor: 1.396 (2015)
40. Umbehr MH, Largo RA, Gfeller S, Tremp M, Poyet C, Paul M, Sulser T, **Müntener M**. Bilaterally positive biopsy cores are associated with non-organ-confined disease in prostate cancer patients eligible for active surveillance.
Urol Int. 2014;93(2):176-81.
Impact factor: 1.313 (2015)

41. Umbehre MH, Lüscher M, Hunziker R, Falkner F, Wild PJ, Poyet C, Seifert B, **Müntener M**. Influence of Varying Assessment Parameters on the Diagnostic Accuracy of Magnetic Resonance Imaging in Local Staging of Prostate Cancer. *Urol Int*. 2016;96(3):309-14.
Impact factor: 1.313 (2015)
42. Umbehre MH, **Müntener M**, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. *Eur Urol*. 2013;64(1):106-17.
Impact factor: 14.976 (2015)
43. Wagner A, **Müntener M**, Makarov D, Nielsen M, Scorpio D, Kavoussi LR. Totally laparoscopic creation of a novel stapled orthotopic neobladder in the porcine model. *J Endourol*. 2008;22(1):151-6.
Impact factor: 2.107 (2015)

2. Fallbeschreibungen

44. **Müntener M**, Hailemariam S, Dubs M, Hauri D, Sulser T. Primary leiomyosarcoma of the seminal vesicle. *J Urol*. 2000;164(6):2027.
45. **Müntener M**, Knönagel H. Die ausgedehnte Urogenital-Tuberkulose. *Schweiz Med Forum*. 2002(7):158-60.
46. Praz V, **Müntener M**, Oechslin E, Weishaupt D, Hauri D, John H. Bilateral perirenal lymphangioma: a conservative approach. *Urol Int*. 2005;74(2):188-9.
47. Romero FR, Chan DY, **Müntener M**, Bagga HS, Brito FA, Kavoussi LR. Laparoscopic heminephrectomy for renal cell carcinoma in cross-fused ectopic kidney. *Urology*. 2007;69(4):779 e11-3.
48. Romero FR, **Müntener M**, Bagga HS, Brito FA, Sulman A, Jarrett TW. Pure laparoscopic radical nephrectomy with level II vena caval thrombectomy. *Urology*. 2006;68(5):1112-4.
49. Romero FR, **Müntener M**, Sulman A, Brito FA, Kavoussi LR. Hemothorax after percutaneous cryoablation of the kidney. *Eur Urol*. 2007;51(3):841-3.
50. Romero FR, Rais-Bahrami S, **Müntener M**, Permpongkosol S, Fine SW, Paidas CN, et al. Metastatic primitive neuroectodermal tumor to the kidney. *Urol Int*. 2007;78(3):286-8.

51. Tremp M, Hafner J, Sulser T, **Müntener M**. Intraurethral Imiquimod for Extensive Urethral Genital Warts (Condylomata Acuminata). BJU Int. 2010:Online.

3. Übersichtsarbeiten

52. Bolleter R, Sulser T, **Müntener M**. [Urological treatment of renal calculi]. Praxis (Bern 1994). 2009;98(25):1517-23.
53. Cathomas R, Schmid HP, Aebbersold D, Amram ML, Berthold D, Eberli D, Gillessen S, Iselin C, Jichlinski P, **Müntener M**, Rentsch C, Schäfer N, Stenner F, Thalmann G, Wild P, Wyler S, Omlin A. Medikamentöse Behandlung des metastasierten Prostatakarzinoms – eine interdisziplinäre Empfehlung. Swiss Medical Forum. 2016;16(11):266–272.
54. Knonagel H, **Müntener M**. [Urolithiasis and ultrasound diagnosis. Value of ultrasound in diagnosis of urolithiasis]. Praxis (Bern 1994). 2002;91(14):603-9.
55. Müller A, **Müntener M**. Erektile Dysfunktion - Aktuelle Stufentherapie und Koexistenz mit Herz-Gefäss-Erkrankungen und metabolischem Syndrom. TMJ. 2007(7):22-7.
56. **Müntener M**. Aktuelles aus der Urologie - Kongressbericht EAU Wien. Medizin Spektrum. 2004(16):38-40.
57. **Müntener M**, Cohen A, Hauri D. Aktuelle Therapie der erektilen Dysfunktion. med. 2004(5,6):7-10, 4-6.
58. **Müntener M**, Cohen A, Hauri D. Aktuelle Therapie der erektilen Dysfunktion. SAR. 2005(3):2-5.
59. **Müntener M**, Suter S, Praz V, Hauri D. [Erectile dysfunction: reasonable diagnostics and treatment in general practice]. Praxis (Bern 1994). 2003;92(5):179-86.
60. **Müntener M**, Ursu D, Patriciu A, Petrisor D, Stoianovici D. Robotic prostate surgery. Expert Rev Med Devices. 2006;3(5):575-84.
61. **Müntener M**, Widmer C. Erektile Dysfunktion. Geriatrie Praxis. 2005(8):21-4.
62. Poyet C, **Müntener M**. Kurative Behandlung des lokalisierten Prostatakarzinoms. Info@Onkologie. 2013;3(4):10-1.

63. Reitz A, **Müntener M**, Haferkamp A, Hohenfellner M, Schurch B. Targeting bladder outlet obstruction from benign prostatic enlargement via the nitric oxide/cGMP pathway?
BJU Int. 2005;96(3):250-3.
64. Strebel RT, **Müntener M**, Sulser T. Intraoperative complications of laparoscopic adrenalectomy.
World J Urol. 2008;26(6):555-60.
65. Umbehrr MH, Grob D, Kienle DL, **Müntener M**. Behandlung des Prostatakarzinoms beim betagten Patienten.
Schweizer Zeitschrift für Onkologie. 2015;2:15-20.
66. Umbehrr MH, Nardi M, Beck S, **Müntener M**, Grob D. Geriatrische Urologie. Der informierte Arzt. 2016;6(7):20-22.
67. Umbehrr MH, Poyet C, **Müntener M**. Kurative Behandlung des lokalisierten Prostatakarzinoms.
InFo Onkologie & Hämatologie. 2014;2(8):15-7.

4. Buchbeiträge

68. Gross O, Sulser T, Hefermehl LJ, Strebel DD, Largo R, Mortezaavi A, Poyet C, Eberli D, Zimmermann M, Müller A, Michel MS, **Müntener M**, Seifert HH, Hermanns T. Ablative efficiency of lithium triborate laser vaporization and conventional transurethral resection of the prostate: A comparison using transrectal three-dimensional ultrasound volumetry. In: N. K, editor. Photonic Therapeutics and Diagnostics VII: Proceedings of SPIE2011.
69. Kranzbuhler B, Gross O, Fankhauser CD, Hefermehl LJ, Poyet C, Largo R, **Müntener M**, Seifert HH, Zimmermann M, Sulser T, Müller A, Hermanns T. Tissue ablation after 120W greenlight laser vaporization and bipolar plasma vaporization of the prostate. A comparison using transrectal three-dimensional ultrasound volumetry. In: Kollias N, editor. Photonic Therapeutics and Diagnostics VIII: Proceedings of SPIE. 82072012.
70. **Müntener M**, Schurch B. Neurologic erectile dysfunction. In: Dunzendorfer U, editor. Sildenafil (Series: Milestones in Drug Therapy). Basel: Birkhäuserverlag; 2004.
71. **Müntener M**, Romero FR, Kavoussi LR. Complications in laparoscopic surgery. In: Hohenfellner M, Santucci R, editors. Emergencies in Urology. Heidelberg: Springer Verlag; 2007.

72. Patriciu A, **Muntener M**, Kavoussi LR, Stoianovici D. Future directions - Image guided robotic assisted interventions. In: de la Rosette J, Manyak M, Harisinghani M, Wijkstra H, editors. Imaging in Urological Oncology. London: Springer Verlag; 2006.

5. Letters

73. **Müntener M**. Kommentar zu: A Practical Diagnostic Approach to Patients with Erectile Dysfunction in the Oral Drug Therapy Era. J Urol Urogynäkol. 2004(4):33.
74. **Müntener M**. Wird die Qualität urologischer Operationen künftig von Laien aus Internetforen beurteilt? Swiss Medical Forum. 2015;15(5253):1226-1227.
75. **Muntener M**, Schaeffer EM, Nielsen ME, Romero FR, Allaf ME, Brito FA, Pavlovich CP, Kavoussi LR, Jarrett TW. Rebuttal from authors re: Peter Albers. Quality criteria of laparoscopic nephroureterectomy. Eur Urol. 2007;51:1481-2. Eur Urol. 2007;51(6):1482-4.
76. **Muntener M**, Schurch B, Reitz A. Response to Comments of Peter F.W.M. Rosier on Michael Muntener, Brigitte Schurch, Bjorn Wefer and Andre Reitz. Systemic Nitric Oxide Augmentation Leads to a Rapid Decrease of the Bladder Outlet Resistance in Healthy Men. Eur Urol. 2006;50(1):117-8.

6. Angeleitete Dissertationen

77. Inaugural-Dissertation zur Erlangen der Doktorwürde der Medizinischen Fakultät der Universität Zürich: „Prostatakarzinom-Früherkennung: Ist eine Reduktion des PSA-Cutoff von 4 ng/ml auf 2,5 ng/ml sinnvoll?“
Vorgelegt von Urs Kunz von Lyssach BE
Arbeit unter Leitung von Dr. med. M. Müntener
Genehmigt auf Antrag von Prof. Dr. med. P. Jaeger

78. Inaugural-Dissertation zur Erlangen der Doktorwürde der Medizinischen Fakultät der Universität Zürich: „Optimierung der Einschlusskriterien für die Active Surveillance Strategie beim Prostatakarzinom“
Vorgelegt von Sabrina Nicole Gfeller von Konolfingen BE
Arbeit unter Leitung von PD Dr. med. M. Müntener
Genehmigt auf Antrag von Prof. Dr. med. T. Sulser

79. Inaugural-Dissertation zur Erlangen der Doktorwürde der Medizinischen Fakultät der Universität Zürich: „Die diagnostische Genauigkeit der Magnetresonanztomographie in der lokalen Bildgebung des Prostatakarzinoms: Eine retrospektive Analyse am Universitätsspital Zürich“
Vorgelegt von Martin Lüscher von Holziken AG
Arbeit unter Leitung von PD Dr. med. M. Müntener
Genehmigt auf Antrag von Prof. Dr. med. T. Sulser